Eaton Vance Management’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Eaton Vance Management’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$16K	–	2098
2021 Q4	$16K	Buy	+100	New	+$16.2K	﹤0.01%	2440
2021 Q3	–	Sell	-100	Closed	-$17K	–	2225
2021 Q2	$17K	Hold	100	–	–	﹤0.01%	2455
2021 Q1	$16K	Buy	+100	New	+$17.1K	﹤0.01%	2171

Other funds holding FBT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.79B AUM 15.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Eaton Vance Management's FBT Position: Q1 2022 in Review

Eaton Vance Management sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q1 2022, closing a stake of 100 shares — an estimated $16K sold.

Eaton Vance Management first reported a position in FBT in Q1 2021 and held it in 3 quarters. The position peaked at $17K in Q2 2021. 220 funds tracked by Wall St. Rank hold FBT as of Q1 2022.

Eaton Vance Management reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 100 First Trust NYSE Arca Biotechnology Index Fund shares in Q1 2022, an estimated $16K.
Eaton Vance Management first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q1 2021 and held it in 3 quarters.
Eaton Vance Management's First Trust NYSE Arca Biotechnology Index Fund position peaked at $17K in Q2 2021.
220 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.